|
| |
TRACON Pharmaceuticals, IncEstablished in 2005 in New York as Lexington Pharmaceuticals, TRACON remains a privately held company. In April 2005, the company named Bert Liang as President and Chief Executive Officer and moved to San Diego, California. The company’s name was changed to TRACON due to the emphasis on targeted therapy for oncologic disease (TaRgeted Approach and Control in Oncology). Dr. Liang now leads a distinguished management team with deep industry credentials and notable achievements including the development and commercialization of several oncology drugs, some of which exceeded $1 billion in sales (e.g., Rituxan and Neulasta).
| Contact Details: |
| 4510 Executive Drive, Suite 330 |
| San Diego |
| California |
| 92121 |
| United States of America |
| Tel: | 858/550-0780 |
| Fax: | 858/550-0786 |
| Email: | bd@traconpharma.com |
| WWW: | www.traconpharma.com/
|
|
Loading...
|
Press Releases on TRACON Pharmaceuticals, Inc:
|
 |
| Micromet Added to Russell 3000 Index |
29th June, 2009 |
Micromet, Inc. |
BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and
|
| Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203 |
18th June, 2009 |
Micromet, Inc. |
BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and
|
| Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients |
8th June, 2009 |
Micromet, Inc. |
German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease
BERLIN, June 8
|
| Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients |
8th June, 2009 |
Micromet, Inc. |
Data Presented at Meeting of European Hematology Association Confirms High Response Rate and Durability of Remissions
BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a
|
| Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009 |
2nd June, 2009 |
Micromet, Inc. |
BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 438 times since April 2007, the link to the organisation's website has been followed 65 times Recent Search Terms used to find this page: tracon | . Search for more companies in San Diego Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for TRACON Pharmaceuticals, Inc |
